FMS

Business Context and Reporting Period

Company: Fresenius Medical Care AG (FME AG)
Filing Type: Form 6-K (Interim Report)
Reporting Period: Three months ended March 31, 2026
Business Overview: The world's leading provider of products and services for individuals with renal diseases. Operations are organized into three segments: Care Delivery (dialysis services), Care Enablement (manufacture and distribution of healthcare products), and Value-Based Care (risk-based kidney care programs).

Key Financial Metrics

Note: Revenue and operating income decreased primarily due to negative foreign currency translation effects and the impact of closed or sold operations, partially offset by organic growth.

Material Changes vs. Prior Period

• Revenue Decline: Consolidated revenue fell 6% (as reported) but grew 3% at constant currency. The decline was driven by foreign currency translation (-9%) and divestitures/closures, offset by organic growth in all segments.
• Operating Income Pressure: Operating income decreased 14% (as reported) and 9% at constant currency. Key drivers included net losses from the FME25+ transformation program (impairment losses from U.S. clinic closures), higher personnel and IT expenses, and inflationary cost increases.
• Segment Performance:
  • Care Delivery: Revenue down 4% (as reported); operating income down 15% due to FME25+ costs and currency effects.
  • Value-Based Care: Recorded an operating loss of €11M compared to €3M income in Q1 2025, driven by FME25+ program losses and contract performance reconciliations.
  • Care Enablement: Revenue down 5% (as reported); operating income down 7% due to currency effects and China market pressures (volume-based procurement), partially offset by 5008X CAREsystem sales.
• Share Buyback: The Company accelerated its €1 billion share buyback program. As of March 31, 2026, 23.3 million shares were repurchased for €347M in the quarter. The program was completed by April 30, 2026.

Guidance, Outlook, and Risks

• FME25+ Program: The expanded transformation program targets €1.2 billion in cumulative sustainable savings by end-2027. Cumulative savings reached €854M as of March 31, 2026.
• Regulatory Environment (U.S.):
  • Reimbursement: CMS finalized a 2.2% increase in ESRD PPS payments for 2026. However, the "One Big Beautiful Bill Act" (OBBBA) signed in July 2025 includes significant Medicaid funding cuts and eligibility restrictions expected to adversely affect reimbursement levels.
  • TDAPA Impact: Transitional Drug Add-on Payment Adjustment (TDAPA) provided favorable support in Q1 2026, but management expects this positive impact to reduce in the second half of 2026.
• Capital Expenditures: Anticipated 2026 CapEx is €0.8–1.0 billion, driven by the rollout of the 5008X CAREsystem (targeting 20% replacement of U.S. machines in 2026) and new production facilities.
• Risks:
  • Geopolitical: Conflict in the Middle East impacting energy prices and supply chains.
  • Trade: New tariffs and trade restrictions creating cost uncertainty.
  • Legal: Ongoing investigations by FTC, DOJ, and state attorneys general regarding antitrust and billing practices; litigation regarding the American Kidney Fund (AKF) premium assistance programs.

Investor Verification Checklist

• Reimbursement Sensitivity: Verify the magnitude of the impact from the OBBBA Medicaid cuts and the expiration of TDAPA transitional payments on future margins.
• FME25+ Execution: Monitor the realization of the targeted €1.2 billion in savings against the rising costs of the transformation program (impairments, restructuring).
• Currency Exposure: Assess the volatility of the Euro/USD exchange rate, given the significant portion of revenue generated in the U.S.
• China Market Dynamics: Review the impact of volume-based procurement and tender requirements on the Care Enablement segment's pricing and volume.
• Legal Contingencies: Track the status of antitrust investigations (FTC/DOJ) and the outcome of the AKF-related litigation in California and other jurisdictions.